Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis
International Journal of Cancer · 2023-02 · 152 (3) · 480-495
DOI: 10.1002/ijc.34332 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 03.11.2022. Verfasst von Tianqi Gu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Neoplasms. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) combined with the anti‐angiogenesis drug bevacizumab is one of the future directions of immunotherapy. However, the potential adverse drug reactions (ADRs) caused by combination therapy remain unclear. Current research on ADRs of combination therapy in cancer patients is extremely limited. Our study aims to help determine the safety of combination therapy. We downloaded the ADR reports on combination therapy, from the first quarter of 2012 to the fourth quarter of 2021, from the FDA adverse event reporting system (FAERS) database and conducted a large‐scale retrospective study. The ADR signals were monitored by reporting odds ratio (ROR) and analyzing the risk of different ADRs in patients with Pan‐cancer. A total of 2094 cases were selected, after excluding duplicate data and the use of chemotherapy drugs. We evaluated the risk of ADR in Pan‐cancer patients. Combination therapy was an independent risk factor for adverse drug reactions associated with interstitial lung disease (OR: 8.62; 95% CI: 6.14‐12.10, P < .0001), hypertension (OR: 1.35; 95% CI: 1.11‐1.65, P < .01) and gastrointestinal bleeding (OR: 3.16; 95% CI: 2.21‐4.51, P < .0001). A subgroup analysis revealed that the risk of endocrine system‐related ADRs was elevated in patients receiving different combination therapies or with certain tumor types. We retrospectively studied the ADR of combination therapy in Pan‐cancer patients and analyzed the distribution characteristics of ADR from the perspectives of treatment strategy and cancer types to provide recommendations for the individualized management of patients receiving combination therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
ORCID-Profile: Quan Cheng, Peng Luo
Zitieren
APA
Gu, T., Jiang, A., Zhou, C., Lin, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2023). Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis. International Journal of Cancer, 152(3), 480-495. https://doi.org/10.1002/ijc.34332
Vancouver
Gu T, Jiang A, Zhou C, Lin A, Cheng Q, Liu Z, et al. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis. International Journal of Cancer. 2023;152(3):480-495. doi:10.1002/ijc.34332
BibTeX
@article{Gu2023,
author = {Gu, Tianqi and Jiang, Aimin and Zhou, Chaozheng and Lin, Anqi and Cheng, Quan and Liu, Zaoqu and Zhang, Jian and Luo, Peng},
title = {Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis},
journal = {International Journal of Cancer},
year = {2023},
volume = {152},
number = {3},
pages = {480--495},
doi = {10.1002/ijc.34332}
}
EUVIMED